Details:
Under the terms of the agreement, Takeda will have exclusive rights to develop and commercialise clinical candidates generated against validated targets derived from the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 25, 2020